Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CorMedix Inc. (CRMD)
|
Add to portfolio |
|
|
|
| Price: |
$9.37
| | Metrics |
| OS: |
54.8
|
M
| |
|
|
| Market cap: |
$514
|
M
| |
|
|
|
Net cash:
|
$52.4
|
M
| |
$0.96
|
per share
|
|
EV:
|
$461
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($29.9)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.2 | 0.2 | 0.3 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 |
| Revenue growth | -20.2% | -15.5% | -34.1% | 30.5% | 47.0% | 6.7% | 11.0% | -95.8% |
| Cost of goods sold | 0.1 | 0.2 | 0.4 | 0.4 | 0.1 | 0.4 | 0.3 | 0.4 |
| Gross profit | 0.0 | 0.0 | -0.1 | 0.0 | 0.2 | -0.1 | -0.1 | -0.3 |
| Gross margin | 22.0% | 14.4% | -31.8% | 7.7% | 65.1% | -63.6% | -51.7% | -135.5% |
| Selling, general and administrative | 16.3 | 13.9 | 9.9 | 8.1 | | | | |
| Research and development | 13.1 | 13.4 | 11.1 | 18.8 | 24.5 | 15.7 | 6.3 | 1.3 |
| General and administrative | | | | | 8.7 | 8.9 | 10.3 | 7.3 |
| EBIT | -29.4 | -27.2 | -21.0 | -26.9 | -32.9 | -24.8 | -16.7 | -8.9 |
| EBIT margin | -15417.5% | -11378.4% | -7416.3% | -6250.4% | -9997.4% | -11048.8% | -7925.6% | -4703.3% |
| Pre-tax income | -29.5 | -27.2 | -21.5 | -26.8 | -33.0 | -24.6 | -18.2 | -20.5 |
| Income taxes | -1.3 | -5.2 | -5.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 4.2% | 19.0% | 23.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -28.2 | -22.0 | -43.5 | -26.8 | -33.0 | -24.6 | -18.2 | -20.5 |
| Net margin | -14774.7% | -9207.7% | -15369.2% | -6242.4% | -10023.4% | -10996.5% | -8671.1% | -10850.1% |
| |
| Diluted EPS | ($0.75) | ($0.77) | ($1.80) | ($1.51) | ($0.60) | ($0.65) | ($0.58) | ($0.96) |
| Shares outstanding (diluted) | 37.7 | 28.6 | 24.2 | 17.8 | 55.1 | 38.0 | 31.3 | 21.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|